Loading...
Market
First major regulatory approval for a product using the new RNA-guided recombinase system by December 31, 2025?
5
Resolution / Starting Odds
FDA (US) • 25%
EMA (Europe) • 25%
NMPA (China) • 25%
Other • 25%
Regulatory bodies' announcements like FDA, EMA, etc.
Story
Arc Institute Unveils New RNA-Guided Mechanism for Genome Design in Nature
Jun 26, 2024, 03:07 PM
Researchers from the Arc Institute have introduced a powerful, programmable new mechanism for genome design using bridge RNAs. This RNA-guided DNA recombinase system enables the precise insertion, excision, or inversion of any two DNA sequences. The discovery, detailed in back-to-back papers published in Nature, represents a significant advancement in the field of genome editing. The new technology allows for modular and programmable DNA modifications, enhancing the power and precision of genome editing for long DNA sequences. Researchers reported the discovery of three atomic structures of the first natural RNA-guided recombinase.
View original story
Similar markets
Illumina • 25%
CRISPR Therapeutics • 25%
Editas Medicine • 25%
Intellia Therapeutics • 25%
FDA (USA) • 25%
EMA (Europe) • 25%
MHRA (UK) • 25%
Other • 25%
Yes • 50%
No • 50%
NTLA-2002 • 25%
Editas Medicine Therapy • 25%
Beam Therapeutics Therapy • 25%
Other • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Wave Life Sciences • 25%
ProQR Therapeutics • 25%
Korro Bio • 25%
Other • 25%
Yes • 50%
No • 50%
Safety warning update • 25%
Clinical trial halt • 25%
No action • 25%
Other action • 25%
